«

»

Apr 26

In vitro antimicrobial efficacy testing: potential pitfalls and future methods

Antimicrobial resistance (AMR) is a global issue, which already causes significant loss of life and will continue to get worse as further resistance evolves. By 2050, it is anticipated that due to AMR alone, 10 million people will die each year, more than currently die from diseases like cancer.

 

Antimicrobial drug pipeline

One of the reasons this issue is so severe is the failing of the antimicrobial drug pipeline. Where only 40% of drugs entering phase 1 clinical trials are making it through the process, investors are cautious to take risks, particularly when resistance can develop soon after launch and return on investment may never happen. Many investors and big pharmaceutical companies are scared off and the pipeline slowed to a crawl.

 

LGC supports the antimicrobial drug pipeline

 

Microbiology experts

LGC works to support the antimicrobial drug pipeline, from high throughput screening and drug development to clinical trial support and on into surveillance. Our microbiology experts work with sponsors to guide their compounds through the process, gathering data on MIC, time-kill, drug activity and other antimicrobial efficacy tests, to identify lead molecules and target organisms.

 

Improved methods for detecting antimicrobial resistance

Current methods are carried out to guideline standards, following dilution methods published by organisations such as the CLSI and EUCAST. However, despite considerable development effort, issues with these methods exist which, may lead to efficacious compounds providing inefficacious data, resulting in their development either being halted or scrapped altogether. LGC is working with EMPIR on a project to define improved methods for detecting AMR, so that in both a clinical and drug development setting, accurate, fast, affordable and reliable data can be generated. Therefore, the drug development pipeline is supported, and the drugs are used most appropriately when they are given to the patient.

 

In vitro antimicrobial efficacy testing webinar

To find out more, register for our webinar on “In vitro antimicrobial efficacy testing: potential pitfalls and future methods” Which is taking place on Wednesday 4th May 2016.

During the webinar Ed Siegwart, Senior Scientist within our Microbiology team at LGC, will discuss the following:

  • Current testing methods being carried out at LGC
  • Pitfalls of the current methods
  • Novel processes, and their potential use
  • Provide an opportunity for Q&A

 

Register for the LGC webinar on In vitro antimicrobial efficacy testing

 

If you have any questions, please do not hesitate to get in touch.

Leave a Reply

%d bloggers like this: